Altagenics

Executive Summary

Altagenics is a newly launched biotechnology company, established in October 2025 by GLD Partners LP, that aims to revolutionize drug discovery for muscle-wasting conditions. The company leverages Heligenics' proprietary GigaAssay™ platform, a high-throughput screening technology capable of analyzing millions of protein-protein interactions simultaneously. This platform enables rapid identification of first-in-class therapeutics for sarcopenia and cachexia, two debilitating conditions characterized by muscle loss due to aging, disease, or drug side effects. Altagenics' initial focus addresses significant unmet medical needs, as there are currently no approved therapies for sarcopenia and limited options for cachexia. The company's approach combines the power of large-scale biological data with advanced computational analysis to accelerate the development of novel treatments. The market opportunity for Altagenics is substantial, given the aging global population and the high prevalence of muscle-wasting disorders. Sarcopenia affects up to 30% of adults over 60, while cachexia impacts millions of cancer patients and those with chronic diseases. However, Altagenics faces early-stage risks, including platform validation, preclinical success, and the need for substantial funding. The company's dependence on the GigaAssay platform and its parent company's support may also pose concentration risks. If successful, Altagenics could establish a leading position in a niche but growing therapeutic area. The next few years will be critical for demonstrating proof-of-concept and attracting further investment.

Upcoming Catalysts (preview)

• TBDCompletion of Initial Target Validation Using GigaAssay60% success
• TBDSeries A Financing Round70% success
• TBDStrategic Partnership for Development or Co-Commercialization50% success